

Prediction of short-term newborn infectious morbidity based on maternal characteristics in patients with PPRM and *Ureaplasma* species infection

Predykcja infekcji u noworodków w oparciu o analizę wyników danych pacjentek z przedwczesnym pęknięciem błon płodowych i infekcją *Ureaplasma*

Mateusz Mikołajczyk¹, Przemysław Krzysztof Wirstlein¹, Magdalena Wróbel², Jan Mazela³, Karolina Chojnacka³, Jana Skrzypczak¹

¹ Department of Gynecology and Obstetrics, Division of Reproduction, Poznan University of Medical Sciences, Poland

² Gynecological and Obstetric Clinical Hospital in Poznan, Poland

³ Department of Neonatology, Poznań University of Medical Sciences, Poland

Abstract

Objectives: Preterm premature rupture of membranes (PPROM) complicates about 5% of pregnancies. *Ureaplasma* species is the most common pathogen found in the amniotic fluid in pregnancy-neonatal outcome. The aim of the following study was to evaluate the impact of colonization with the *Ureaplasma* spp. on pregnant women with PPRM, coinfection with different microorganisms, and antimicrobial treatment on neonatal outcome.

Material and methods: The study included 30 women with PPRM hospitalized in Division of Reproduction in a complicated by PPRM. It is speculated that it requires a coinfection to produce unfavorable outcome. The study was conducted in the Department of Gynecology and Obstetrics, Division of Reproduction, Poznan's K. Marcinkowski University of Medical Sciences. Swabs from cervical canal were obtained for the identification of bacterial and ureaplasmatic infections by culture and PCR.

Results: The presence of any infection during the pregnancy after PPRM was confirmed in 22 patients (*Ureaplasma* spp. in 12 patients, coinfection in 10 women). The cure rate for *Ureaplasma* species and other infections was 17% (2/12 patients) and 23% (5/22 patients), respectively. There was no correlation between *Ureaplasma* species infection, coinfection, and cure status with the infection in the newborn. The PPRM to delivery duration also did not affect the newborn infection status. A negative relationship with leukocyte level was detected in patient with newborn infection.

Conclusions: The presence of colonization with *Ureaplasma* species is not attributable to neonatal short-term morbidity. The evaluation of maternal biochemical and microbiological data, regardless of the duration of the pregnancy after PPRM or the cure status, does not add any insight into the newborn infection status.

Key words: **PPROM / short-term newborn infectious / *Ureaplasma* spp. /**

Adres do korespondencji:

Przemysław Krzysztof Wirstlein

Department of Gynecology and Obstetrics, Division of Reproduction, Poznan University of Medical Sciences

Poland, 60-535 Poznań, ul. Polna 33

tel.: +48 61 8419302; fax: +48 61 8419625; e-mail: abys@wp.pl

Otrzymano: 03.03.2015

Zaakceptowano do druku: 01.04.2015

Mateusz Mikołajczyk et al. Prediction of short-term newborn infectious morbidity based on maternal characteristics in patients with PPRM and *Ureaplasma* species infection.

Streszczenie

Cel pracy: Przedwczesne pęknięcie błon płodowych wikła około 5% wszystkich ciąż i wiąże się z ryzykiem zapalenia błon płodowych oraz zagrożenia porodem przedwczesnym. *Ureaplasma species* jest patogenem najczęściej występującym w płynie owodniowym ciąż powikłanych PPRM. Wyjaśnienie wpływu koinfekcji na niekorzystne wyniki neonatologiczne wymaga dalszych badań. Celem pracy była ocena wpływu kolonizacji *Ureaplasma species*, koinfekcji innymi drobnoustrojami i leczenia przeciwbakteryjnego w ciążach powikłanych PPRM na wyniki neonatologiczne.

Materiał i metody: Badaniem objęto 30 pacjentek hospitalizowanych w Klinice Rozrodczości Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. Pobierano wymazy z szyjki macicy celem identyfikacji infekcji bakteryjnej i ureaplazmatycznej metodą hodowlaną oraz PCR.

Wyniki: Infekcję potwierdzono u 22 pacjentek z PPRM (*Ureaplasma spp.* rozpoznano u 12 pacjentek, natomiast koinfekcję u 10). Odsetek wyleczenia zakażenia *Ureaplasma* i innymi drobnoustrojami wyniósł odpowiednio 17% (2/12) i 23% (5/22). Nie stwierdzono korelacji między zakażeniem *Ureaplasma*, koinfekcją, a występowaniem zakażeń u noworodków, niezależnie od statusu wyleczenia. Nie wykazano istotnych różnic między długością czasu od PPRM do porodu, a obecnością infekcji u noworodka. Udowodniono odwrotnie proporcjonalną zależność między poziomem leukocytów u pacjentek, a występowaniem zakażenia u noworodka.

Wnioski: Brak zależności między kolonizacją *Ureaplasma* u pacjentek z PPRM, a krótkoterminową zachorowalnością noworodków. Ocena czynników biologicznych i mikrobiologicznych nie pozwala na przewidzenie stanu noworodka.

Słowa kluczowe: PPRM / zakażenia u wcześniaków / *Ureaplasma spp.* /

Preterm premature rupture of membranes (PPROM) complicates about 5% of pregnancies and is considered a cause of premature labor in 40–60% of cases [1]. Infection is the most commonly cited cause for PPRM [2]. In turn, chorioamnionitis is the most common and serious complication of PPRM. According to different reports, it occurs in 10–60% of preterm membrane rupture cases [3, 4]. The longer the interval from PPRM to delivery, more likely the chorioamnionitis will occur. Therefore, PPRM poses clinician with a therapeutic dilemma—should labor occur early after rupture of membranes, often producing a premature newborn with inherent problems of prematurity, or should the labor be postponed, with possible development of intraamniotic infection—and its own set of problems. Apart from standard infections with aerobic and anaerobic bacteria, there is a threat of infection with *Ureaplasma* species. This pathogen is said to be a part of urogenital flora in up to 25% of patients with premature rupture of membranes [5]. The distinguishing features of this mycoplasma are as follows: smallest size, lack of cell wall, and resistance to commonly prescribed antibiotics, including beta-lactams [6, 7]. The incidence of vertical transmission of *Ureaplasma* infection in term newborns without respiratory disorders was assessed at 38% [8]. The contribution of *Ureaplasma spp.* to neonatal disease (including pneumonia and respiratory distress syndrome) is conflicting. It has been confirmed that there is a presence of *Ureaplasma spp.* in cases of PPRM, but it has been suggested that evidence of the mere presence is not enough to be causative of a disease [9]. It is speculated that it might require a coinfection to produce unfavorable neonatal outcome.

The objective of our study was to determine whether colonization of the vagina with *Ureaplasma spp.* of pregnant women with PPRM was associated with adverse neonatal outcome. Furthermore, we aimed at determining if successful antimicrobial treatment had any effect on decreasing the incidence of infection in newborns, and if a coinfection with different microorganism induced different problems during the neonatal period.

Material and method

The study was conducted in Division of Reproduction and Neonatal Infection Ward in Poznan's K. Marcinkowski University of Medical Sciences. The study included 30 women with PPRM, which is defined as rupture occurring between 24–34th week of gestation. Exclusion criteria were as follows: fetus with congenital anomalies, marked hypotrophy of the fetus, amniocentesis in current pregnancy. The mean age of the patients was 33 years (24–44 years old). There were 5 primiparous and 25 multiparous patients, respectively. The mean time of the membrane rupture was 31 weeks' gestation (18–34 weeks' gestation). The rupture-to-delivery interval was 10 days (3–79 days) and the mean week of delivery was 33rd week of gestation (28–36 weeks' gestation). The protocol involved placing a sterile speculum in the vagina at the time of admission and collection of leaking amniotic fluid from cervical canal to a sterile swab (two standard dry ones and one with culture media). The swabs were sent to Microbiology Unit in our hospital for the identification of bacterial and ureaplasmatic infections. In addition, the DNA was extracted and PCR was carried out to test for the presence of *Ureaplasma spp.* in amniotic fluid.

Collection the amniotic fluid from the cervical canal.

Using sterile swabs, we collected samples from the cervical canal. Two swabs were sent to the microbiological unit for analysis. Another swab, intended to identify bacteria by qPCR, was frozen (–200°C) until assay.

Identification of the *Ureaplasma spp.* in PCR assay.

Swab was suspended in 1.5 ml of sterile saline (0.9% NaCl). DNA isolation was conducted with the obtained suspension of 200 µl, using QIAamp MiniElute Virus Spin Kit Qiagen (Hilden, Germany). The identification of *Ureaplasma parvum* or/and *Ureaplasma urealyticum* DNA was conducted using FTD urethritis plus detection kit (Fast-track Diagnostics, Luxembourg), containing specific primers and fluorescent probes and RotorGene

Mateusz Mikolajczyk et al. Prediction of short-term newborn infectious morbidity based on maternal characteristics in patients with PPROM and *Ureaplasma* species infection.**Table 1.** The incidence of infection, results of treatment, and markers of inflammation in infected and healthy newborns.

	Infected newborns	Non-infected newborns	<i>p</i>
<i>Ureaplasma</i> spp. infections during PPROM			Chi ² w. Yates correction
<i>Ureaplasma</i> spp. positive	5	7	0,940
<i>Ureaplasma</i> spp. negative	9	9	
<i>Ureaplasma</i> treatment result during PPROM			Fisher's Exact Test
<i>Ureaplasma</i> spp. cured	2	0	0,470
<i>Ureaplasma</i> spp. not cured	5	5	
Infection with other pathogens than <i>Ureaplasma</i> spp.			Fisher's Exact Test
Cured	2	3	0,624
Not cured	10	7	
CRP [mg/L] median (range)	9,56 (1,4-222,9)	4,00 (1,1-17,8)	0,661*
	OR=1,069 95%CI (0,93-1,228)		0,39
WBC [G/L] median (range)	9,87 (5,8-15,3)	15,23 (3,7-32,6)	0,038*
	OR=0,79, 95%CI (0,6250,999)		0,049**
The PPROM to delivery length [days] median (range)	13 (3-79)	9 (2-37)	0,183*
	OR=1,03, 95%CI (0,987-1,087)		0,158**

*Mann-Whitney Rank Sum Test, **Logistic Regression Analysis.

3000 thermocycler (Corbett Research, Australia) according to the protocol and thermal profile of the PCR reaction supplied by the manufacturer.

All the patients received a standard treatment consisting of ampicillin 1 g q 6 h and erythromycin 300 mg three times daily. If the presence of *Ureaplasma* spp. was confirmed, the patients were subject to additional treatment with azithromycin two times 500 g/day for three days. Curative treatment was defined as lack of the presence of pathogens in the last culture immediately preceding the delivery. The cervical canal swab was repeated every 7 day until delivery in each patient. The patients were monitored using CTG(cardiotocography), Doppler studies, and biochemical indices (WBC, CRP) to detect any signs of fetal distress or infection. The decision to deliver was left to the discretion of managing physician. The study group comprised 24 women with preterm PPROM. All newborns after delivery were evaluated for signs of infection.

For the statistical evaluation of the results, SigmaStat 3.5 (Dundas Software Ltd., Germany) was used. To examine the statistical significance of the variable distribution, the chi-square test with Yates correction and Fisher's Exact Test was used. We assumed $p < 0.05$ for statistical significance.

Results

Obtained results are summarized in Table 1. The presence of any infection at some point during the pregnancy after PPROM was confirmed in 22 patients. The presence of *Ureaplasma* species was confirmed in 12 patients while coinfection with other pathogens was found in 10 women with PPROM.

The cure rate, defined as no infection in cervical culture before delivery, for *Ureaplasma* species was 17% (2/12 patients), and cure rate for other infections was 23% (5/22 patients).

There was no correlation with *Ureaplasma* spp. infection during the PPROM-to-delivery interval and infections detected in newborns. Furthermore, there was no statistically significant difference in the presence of infections in the newborn and successful treatment of *Ureaplasma* colonization. Also no correlation was found between coinfection with other pathogens and infection in the newborn, regardless of cure status.

Regarding the CRP and leukocyte levels, using logistic regression analysis, we have detected a negative relationship with leukocyte levels in patients with newborn infection. The lower the leukocyte count, the more likely was the infection of the newborn to be detected (OR = 0,79; $p = 0,49$). The PPROM to delivery length also did not affect the newborn infection status (OR = 1,03; $p = 0,158$).

Discussion

PPROM and associated preterm labor remains one of the most challenging aspects of modern perinatal medicine. One of the most common complications of preterm PPROM is ascending infection. The role of *Ureaplasma* spp. as a causative factor for PPROM and pathogen responsible for neonatal adverse effects is still debatable. In our study, the rate of confirmed *Ureaplasma* spp. infection in patients with PPROM was 33,6% (12 patients). This is in line with the lowest estimates of *Ureaplasma* colonization during pregnancy [10]. We have utilized both culture and PCR to detect *Ureaplasma* in cervical swabs. There is some controversy regarding the presence of *Ureaplasma* in different compartments. The rate of colonization might be different for vaginal swabs, cervical samples, direct amniotic fluid samples, and, finally, the cord blood taken during cordocentesis. Our aim was to provide an easy and affordable method to estimate the bacterial burden in patients with PPROM. Most studies focus on

Mateusz Mikołajczyk et al. Prediction of short-term newborn infectious morbidity based on maternal characteristics in patients with PPRM and *Ureaplasma* species infection.

the cervical canal as it is the “passage” between the intrauterine and vaginal compartments. The vaginal flora is often responsible for the ascending infection, while the draining amniotic fluid gives us clues as to what is the situation within the amniotic sac and, therefore, in the fetus. This was recently confirmed by Kacerovsky et al. as they confirmed that 80% of women with *Ureaplasma* infection in the cord blood had also exhibited the infection in the amniotic fluid [11]. However, the range of *Ureaplasma* colonization in the setting of PPRM is very wide – from 15% to 68% [12, 13]. This wide variation might reflect the differences in socioeconomic and geographic variations in the prevalence in the *Ureaplasma* infection.

Contrary to some authors, we have found no correlation between *Ureaplasma* colonization and neonatal infection [14, 15]. This was also true for patients with and without eradication of the pathogen at the time of delivery. Also no correlation was found between the week of preterm delivery and infection status in the newborn. Our results strengthen the recent study by Kacerovsky et al. They have failed to detect any impact on short-term neonatal morbidity with regard to cord blood presence of *Ureaplasma* spp. This might be explained by the fact that according to some studies, the *Ureaplasma* does not induce an inflammatory reaction [16]. Therefore, the fetal inflammatory reaction might not be observed in the mere presence of *Ureaplasma* species. However, we have also confirmed that 10 women with PPRM were also infected with other pathogens, which were treated according to antibiogram. After the correction for this fact, we have also failed to see a correlation between the infection in the neonate and the eradication rate for different bacterial species detected with the cervical swab. The cure rate in our current study for *Ureaplasma* was 17% and for other bacteria 23%. The relatively low cure rate might be partially explained by the fact that the mean rupture to delivery time was only 10 days (shortest time being 3 days). Also, the extreme long times to delivery achieved in some patients (79 days) were conducive to ascending infection. The fetus, having only IgG antibodies crossing from the mother to defend itself from infection, constitutes a perfect feeding ground for any bacteria. Most of the studies look at this aspect not with repeat PCR as a proof of cure, but rather with observation of decline in adverse effects (preterm birth, infection in the newborn). This approach has a serious flaw as demonstrated by elegant study by Ogasawara et al. [17]. It proved that the cure rate as estimated by the vertical transmission rates was not different; however, a prolongation of pregnancy was achieved. By using antibiotics we are not only affecting the presence of *Ureaplasma*. Antibiotics exert their action on a wide range of bacteria; therefore, the observed improvements in adverse effects might be attributable to eradicating different bacterial species [18]. Also the biological effects of antibiotics reach far above the antimicrobial actions in the human organism.

Conclusions

In summary, in this paper we present supporting evidence to a thesis that mere presence of colonization with *Ureaplasma* species is not attributable to neonatal short-term morbidity. Also the currently prevailing believe, that achieving improvement in neonatal outcomes with antibiotic treatment is attributable to eradication of *Ureaplasma* is questionable, as we have achieved very low cure rates, proven by repeated sampling of the cervical

environment. Currently, we do not have any insight into the newborn infection status, as judged by the maternal biochemical and microbiological data, regardless of the duration of the pregnancy after PPRM or the cure status. Therefore, optimal course of action in preterm PPRM, which is early versus delayed delivery, still remains unknown.

Oświadczenie autorów

1. Mateusz Mikołajczyk – współautor koncepcji i założeń pracy, przygotowanie manuskryptu – autor głośzący i odpowiedzialny za manuskrypt.
2. Przemysław Krzysztof Wirstlein – oznaczenia laboratoryjne, analiza statystyczna.
3. Magdalena Wróbel – przygotowanie, korekta ostatecznego kształtu manuskryptu.
4. Jan Mazela – ocena stanu noworodka, przekazanie danych dotyczących noworodka.
5. Karolina Chojnacka – ocena stanu noworodka, przekazanie danych dotyczących noworodka.
6. Jana Skrzypczak – utor koncepcji i założeń pracy, oraz protokołu, korekta, zebranie materiału.

Źródło finansowania: Praca była finansowana z Badań statutowych Kliniki Rozrodczości nr: 502-01-01110142-00304.

Konflikt interesów: Autorzy nie zgłaszają konfliktu interesów oraz nie otrzymali żadnego wynagrodzenia związanego z powstawaniem pracy.

References

1. Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. *Obstet Gynecol Clin North Am.* 2005, 32, 411-428.
2. Romero R1, Miranda J, Chaemsithong P, [et al.]. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabour rupture of membranes. *J Matern Fetal Neonatal Med.* 2014, 29, 1-16.
3. Xie A, Zhang W, Chen M, [et al.]. Related factors and adverse neonatal outcomes in women with preterm premature rupture of membranes complicated by histologic chorioamnionitis. *Med Sci Monit.* 2015, 21, 390-395.
4. Wojcieszek AM, Stock OM, Flenady V. Antibiotics for prelabour rupture of membranes at or near term. *Cochrane Database Syst Rev.* 2014, 29, 10.
5. Goldenberg RL1, Andrews WW, Goepfert AR, [et al.]. The Alabama Preterm Birth Study: umbilical cord blood *Ureaplasma* species and *Mycoplasma hominis* cultures in very preterm newborn infants. *J Obstet Gynecol.* 2008, 43, 1-5.
6. Cassell GH1, Davis JK, Waites KB, [et al.]. Pathogenesis and significance of urogenital mycoplasmal infections. *Adv Exp Med Biol.* 1987, 224, 93-115.
7. Tomasiak A, Heczko PB, Janeczko J, [et al.]. Bacterial infections of the lower genital tract in fertile and infertile women from the southeastern Poland. *Ginekol Pol.* 2013, 84, 352-358.
8. Biernat-Sudolska M, Rojek-Zakrzewska D, Rzepecka-Weglarz B, Kosz-Vnenchak M. Evaluation of vertical transmission of two species of ureaplasmas in term newborns without respiratory disorders - a preliminary study. *Ginekol Pol.* 2011, 82, 359-362.
9. Capoccia R1, Greub G, Baud D. *Ureaplasma* species, *Mycoplasma hominis* and adverse pregnancy outcomes. *Curr Opin Infect Dis.* 2013, 26, 231-240.
10. Carroll SG, Papaioannou S, Ntumazah IL, [et al.]. Lower genital tract swabs in the prediction of intrauterine infection in preterm prelabour rupture of the membranes. *J Obstet Gynaecol* 1996, 103, 54-59.
11. Kacerovsky M, Pliskova L, Menon R, [et al.]. Microbial load of umbilical cord blood *Ureaplasma* species and *Mycoplasma hominis* in preterm prelabour rupture of membranes. *Maternal fetal neonatal medicine.* 2014, 27, 1627-1632.
12. Gauthier DW, Meyer WJ, Bieniarz A. Expectant management of premature rupture of membranes with amniotic fluid cultures positive for *Ureaplasma* species alone. *Am J Obstet Gynecol.* 1994, 170, 587-590.
13. Kacerovsky M, Pavlovsky M, Tosner J, [et al.]. Preterm premature rupture of the membranes and genital mycoplasmas. *Acta Medica.* 2009, 52, 117-120.
14. Kafetzis DA, Skevaki CL, Skouteri V, [et al.]. Maternal genital colonization with *Ureaplasma* species PPRM/otes preterm delivery: association of the respiratory colonization of premature infants with chronic lung disease and increased mortality. *Clin Infect Dis.* 2004, 39, 1113-1122.
15. Hassanein SM, El-Farrash RA, Hafez HM, [et al.]. Cord blood interleukin-6 and neonatal morbidities among preterm infants with PCR-positive *Ureaplasma* species. *J Matern Fetal Neonatal Med.* 2012, 25, 2106-2110.
16. Pellier MR, Drobek CO, Bhat G, [et al.]. Amniotic fluid and maternal race influence responsiveness of fetal membranes to bacteria. *J Reprod Immunol.* 2012, 96, 68-78.
17. Ogasawara KK, Goodwin TM. The efficacy of prophylactic erythromycin in preventing vertical transmission of *Ureaplasma* species. *Am J Perinatol.* 1997, 14, 233-237.
18. Baud D, Thomas V, Arafa A, [et al.]. *Waddlia chondrophila*, a potential agent of human fetal death. *Emerg Infect Dis.* 2007, 13, 1239-1243.